天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600161 天坛生物

已收盘 08-26 15:00:00

{"stockData":{"symbol":"600161","market":"SH","secType":"STK","nameCN":"天坛生物","latestPrice":12.52,"timestamp":1787727601000,"preClose":12.32,"halted":0,"volume":17191234,"delay":0,"changeRate":0.0162,"floatShares":1977000000,"shares":1977000000,"eps":0.4919,"marketStatus":"已收盘","change":0.2,"latestTime":"08-26 15:00:00","open":12.3,"high":12.64,"low":12.27,"amount":215000000,"amplitude":0.03,"askPrice":12.52,"askSize":418,"bidPrice":12.51,"bidSize":279,"shortable":0,"etf":0,"ttmEps":0.4919,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.32,"symbolType":"stock","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":13.55,"lowLimit":11.09,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1977371446,"isCdr":false,"pbRate":2.09,"roa":"--","peRate":25.452328,"roe":"1.07%","epsLYR":0.55,"committee":-0.639491,"marketValue":24757000000,"turnoverRate":0.0087,"status":0,"floatMarketCap":24757000000},"requestUrl":"/m/hq/s/600161/tweets","defaultTab":"tweets","newsList":[{"id":"2655780738","title":"股市必读：天坛生物（600161）7月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655780738?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:32","pubTimestamp":1785432730,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，天坛生物报收于12.83元，上涨2.15%，换手率0.81%，成交量15.98万手，成交额2.04亿元。董秘最新回复投资者： 公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0188","BK0028","BK0168","BK0185","BK0239","BK0046","600161","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820555","title":"天坛生物：将持续完善研发全流程质量管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820555?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404718,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：优化细胞与基因治疗药品审评审批(征求意见稿)对天坛生物公司的研发有何影响？天坛生物回复：感谢您对公司的关注。公司将密切关注法规更新与监管导向，持续完善研发全流程质量管理体系，严守合规管理要求，明确研发品种临床价值定位，充分利用法规创新政策加速成果转化。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0168","BK0239","BK0010","600161","BK0185","BK0082","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655322820","title":"天坛生物：公司未开展相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655322820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655322820?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404718,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘先生，贵公司有无开展人类寿命延长的生物制品？目前全球顶尖生物技术研究发现，人类血液中存在长生因子，通过提炼，可以实现人类的身体机能年轻化。天坛生物回复：感谢您对公司的关注。公司未开展相关工作。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0168","BK0188","BK0082","BK0046","BK0185","600161","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354820","title":"天坛生物：第四代层析工艺10%浓度“静注人免疫球蛋白”已获上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354820","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354820?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404713,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。天坛生物回复：感谢您对公司的关注。公司下属成都蓉生研制的第四代层析工艺 10%浓度“静注人免疫球蛋白” 已于2023年获得上市许可，目前正在积极开展相关产品的市场拓展工作。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0168","BK0188","BK0028","600161","BK0185","BK0046","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745926","title":"天坛生物：公司应收账款风险均可控","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745926?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:57","pubTimestamp":1784800641,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。价格战何时见底？\"脱浆\"技术能否兑现？管理层今年是否实现。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0168","BK0082","BK0028","600161","BK0239","BK0010","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653399745","title":"天坛生物：2025年9月管理级别提升为二级公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2653399745","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653399745?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:45","pubTimestamp":1784799915,"startTime":"0","endTime":"0","summary":"2025年9月，国药集团将公司管理级别由三级公司提升为二级公司，公司战略地位、资源获取能力进一步提升，治理架构进一步优化，公司依托央企股东背景实现快速发展的优势显著增强。按照股权关系，中国生物技术股份有限公司为公司控股股东，中国医药集团有限公司为公司实际控制人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0010","BK0185","BK0082","BK0046","600161","BK0188","BK0168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745887","title":"天坛生物：夯实血源根基，力争采浆量达到3000吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745887?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:42","pubTimestamp":1784799734,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0188","600161","BK0082","BK0028","BK0046","BK0168","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653743749","title":"天坛生物：2026年加大改革力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2653743749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653743749?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:36","pubTimestamp":1784799378,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。2026年，公司正在加大改革力度，重点围绕血源、营销、研发、管理等四个维度，多措并举推动效率提升，持续增强核心竞争力、盈利能力。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0010","600161","BK0028","BK0046","BK0239","BK0188","BK0168","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653437127","title":"天坛生物：市值管理的核心是价值创造","url":"https://stock-news.laohu8.com/highlight/detail?id=2653437127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653437127?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:36","pubTimestamp":1784799370,"startTime":"0","endTime":"0","summary":"天坛生物的各管理层对如今的国企央企市值管理有何看法？市值管理的核心是价值创造，当前，血液制品行业正处于调整期，但长期利好的趋势没有改变；公司持续围绕主营业务，以价值创造为核心，并通过精益管理提升运营效率、加大现金分红力度、不断提高信息披露质量、加强投资者关系管理等方式，努力推动公司投资价值合理反映公司质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0168","BK0082","BK0010","BK0046","BK0239","BK0185","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653743933","title":"天坛生物：持续推动国产血液制品在神经专科和老年科赛道纵深布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2653743933","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653743933?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:24","pubTimestamp":1784798667,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。依托本次中欧学术交流会，天坛生物搭建起临床医疗机构、权威科研院所与血液制品企业协同对话的专业平台。未来，公司将持续深耕人血白蛋白、静注人免疫球蛋白的创新临床转化，持续推动国产血液制品在神经专科和老年科赛道纵深布局，满足患者用药需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0046","BK0185","BK0188","BK0168","BK0082","600161","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653743919","title":"天坛生物：皮下注射人免疫球蛋白已获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653743919","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653743919?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:24","pubTimestamp":1784798665,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问国内市场独家产品“皮下静注人免疫球蛋白”有上市销售了吗？公司对新药品有哪些规划布局和既定经营目标？天坛生物回复：感谢您对公司的关注。公司“皮下注射人免疫球蛋白”已获得《药品注册证书》，并已通过药品GMP符合性检查，可进行该产品的生产、上市和销售。目前，该产品尚未实现销售，根据血液制品生产工艺，该产品从投浆到送批签发合格，需要一定时间。公司新组建免疫球蛋白专队，加强新产品学术推广。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600161","BK0188","BK0082","BK0168","BK0046","BK0185","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652372972","title":"每周股票复盘：天坛生物（600161）上半年净利预降超51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652372972","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652372972?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:51","pubTimestamp":1784397068,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，天坛生物报收于12.52元，较上周的12.08元上涨3.64%。本周，天坛生物7月16日盘中最高价报13.0元。本周关注点来自业绩披露要点：天坛生物预计2026年上半年扣非净利润约2.91亿元。公司公告汇总北京天坛生物制品股份有限公司预计2026年半年度实现归属于母公司所有者的净利润为30,522.88万元，同比下降51.75%左右；扣除非经常性损益的净利润为29,113.28万元，同比下降52.89%左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0185","BK0168","BK0239","BK0082","BK0010","BK0046","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289824","title":"天坛生物（600161）披露2025年年度权益分派实施公告，7月17日股价下跌3.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652289824?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:16","pubTimestamp":1784297782,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，天坛生物报收于12.52元，较前一交易日下跌3.32%，最新总市值为247.57亿元。该股当日开盘12.89元，最高13.0元，最低12.52元，成交额达2.67亿元，换手率为1.07%。近日，公司披露《2025年年度权益分派实施公告》，宣布以总股本1,977,371,446股为基数，每股派发现金红利0.05元（含税），共计派发98,868,572.30元（含税）。分派对象为截至股权登记日在中国结算上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0168","BK0239","BK0010","600161","BK0185","BK0082","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651459323","title":"天坛生物（600161）披露2026年半年度业绩预告，7月15日股价上涨2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651459323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651459323?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:31","pubTimestamp":1784107916,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，天坛生物报收于12.59元，较前一交易日上涨2.19%，最新总市值为248.95亿元。该股当日开盘12.15元，最高12.72元，最低12.12元，成交额达3.12亿元，换手率为1.26%。公司于2026年7月15日披露《2026年半年度业绩预告》。公告显示，北京天坛生物制品股份有限公司预计2026年半年度实现归属于母公司所有者的净利润为30,522.88万元，同比下降51.75%左右；扣除非经常性损益的净利润为29,113.28万元，同比下降52.89%左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500033800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600161","BK0188","BK0168","BK0082","BK0028","BK0239","BK0185","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651103318","title":"天坛生物：预计2026年1-6月扣非后净利润盈利约2.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651103318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651103318?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:03","pubTimestamp":1784030590,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物发布业绩预告，预计2026年1-6月扣非后净利润盈利约2.91亿元。天坛生物2026年一季报显示，一季度公司主营收入11.42亿元，同比下降13.36%；归母净利润1.26亿元，同比下降48.45%；扣非净利润1.13亿元，同比下降52.6%；负债率7.07%，投资收益552.08万元，财务费用37.02万元，毛利率34.59%。本文数据来源于《天坛生物:天坛生物2026年半年度业绩预告》，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647320671","title":"天坛生物最新公告：下属企业获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2647320671","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647320671?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:43","pubTimestamp":1782726215,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称，公司下属成都蓉生研制的250IU/瓶、500IU/瓶规格的“注射用重组人凝血因子Ⅷ”收到国家药监局签发的《药品补充申请批准通知书》，后续需通过GMP符合性检查后方可生产。该产品为已上市产品新增规格，有助于满足临床不同需求，但未来生产受政策、市场等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900027369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0168","BK0188","BK0082","BK0046","BK0185","600161","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644906501","title":"每周股票复盘：天坛生物（600161）现1笔大宗交易 机构净卖出948.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644906501","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644906501?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:26","pubTimestamp":1781897173,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，天坛生物报收于12.31元，较上周的12.87元下跌4.35%。本周，天坛生物6月15日盘中最高价报13.08元。6月18日盘中最低价报12.18元。天坛生物当前最新总市值243.41亿元，在生物制品板块市值排名9/51，在两市A股市值排名893/5206。报告回顾了2025年经营情况，包括营收增长、采浆量领先、生产质量达标、科技创新进展及国际化布局。提出2026年工作思路，聚焦战略规划、决策优化、风险防控与经营提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0239","BK0082","BK0185","BK0028","BK0010","BK0188","BK0046","600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644823880","title":"天坛生物（600161）披露2025年年度股东会会议文件，6月18日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644823880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644823880?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:56","pubTimestamp":1781794576,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，天坛生物报收于12.31元，较前一交易日下跌0.08%，最新总市值为243.41亿元。该股当日开盘12.3元，最高12.55元，最低12.18元，成交额达1.37亿元，换手率为0.56%。近日，北京天坛生物制品股份有限公司发布2025年年度股东会会议文件，包含董事会工作报告、利润分配方案、续聘会计师事务所、修订公司章程及议事规则、董事与高管薪酬管理制度等多项议案。同时披露独立董事履职情况、董事会成员提名及薪酬安排。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800043080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0168","BK0188","BK0082","BK0046","BK0185","600161","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643274293","title":"6月15日天坛生物现1笔大宗交易 机构净卖出948.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643274293","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643274293?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:52","pubTimestamp":1781517164,"startTime":"0","endTime":"0","summary":"证券之星消息，6月15日天坛生物发生大宗交易，交易数据如下：大宗交易成交价格12.87元，相对当日收盘价溢价1.26%，成交73.73万股，成交金额948.93万元，买方营业部为瑞银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为机构专用。近三个月该股共发生1笔大宗交易，合计成交7373.0手，溢价成交1笔。截至2026年6月15日收盘，天坛生物报收于12.71元，下跌1.24%，换手率1.08%，成交量21.44万手，成交额2.74亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500023196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0168","BK0028","BK0082","BK0046","BK0239","BK0188","600161","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641488083","title":"天坛生物最新公告：下属企业获国内首个皮下注射人免疫球蛋白药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641488083","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641488083?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:51","pubTimestamp":1780912313,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称，公司下属成都蓉生研制的“皮下注射人免疫球蛋白”获国家药监局批准生产，该产品为国内首个同类产品，用于治疗≥2岁原发性免疫缺陷病。此次获批将丰富公司产品线，但未来销售受政策及市场影响存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0168","BK0082","600161","BK0188","BK0028","BK0010","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787768680088,"stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0187},{"period":"3month","weight":-0.0383},{"period":"6month","weight":-0.2293},{"period":"1year","weight":-0.3856},{"period":"ytd","weight":-0.2307}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0141},{"period":"3month","weight":-0.0454},{"period":"6month","weight":-0.0601},{"period":"1year","weight":0.0114},{"period":"ytd","weight":-0.0142}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京天坛生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"88197人(较上一季度减少0.02%)","perCapita":"22419股","listingDate":"1998-06-16","address":"北京市大兴区北京经济技术开发区博兴二路6号院8号楼521室","registeredCapital":"197737万元","survey":"　　北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品，开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白（pH4）、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。","listedPrice":4.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天坛生物,600161,天坛生物股票,天坛生物股票老虎,天坛生物股票老虎国际,天坛生物行情,天坛生物股票行情,天坛生物股价,天坛生物股市,天坛生物股票价格,天坛生物股票交易,天坛生物股票购买,天坛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}